The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-04. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In a prebiotic context, they argued that seawater would likely still be buffered and ferrous iron could inhibit oxidation. Steam and hydrogen sulfide. In 1999, after Miller suffered a stroke, he donated the contents of his laboratory to Bada. In an old cardboard box, Bada discovered unanalyzed samples from modified experiments that Miller had conducted in the 1950s. In a "volcanic" apparatus, Miller had amended an aspirating nozzle to shoot a jet of steam into the reaction chamber. Using high-performance liquid chromatography and mass spectrometry, Bada's lab analyzed old samples from a set of experiments Miller conducted with this apparatus and found some higher yields and a more diverse suite of amino acids. Bada speculated that injecting the steam into the spark could have split water into H and OH radicals, leading to more hydroxylated amino acids during Strecker synthesis. In a separate set of experiments, Miller added hydrogen sulfide (H2S) to the reducing atmosphere, and Bada's analyses of the products suggested order-of-magnitude higher yields, including some amino acids with sulfur moieties. Free electrons and charged microdroplets. A 2021 work highlighted the importance of the high-energy free electrons present in the experiment. It is these electrons that produce ions and radicals, and represent an aspect of the experiment that needs to be better understood. A 2025 study used charges from sprays of water instead of lightning to produce electricity.
=== Saxon era === A minster was founded in the 8th century at Westbury on Trym and is mentioned in a charter of 804. In 946 an outlaw named Leof killed Edmund I in a brawl at a feast in the royal palace at Pucklechurch, which lies about six miles from Bristol. The town of Bristol was founded on a low hill between the rivers Frome and Avon at some time before the early 11th century. The main evidence for this is a coin of Aethelred issued c. 1010. This shows that the settlement must have been a market town and the name Brycg stowe indicates "place by the bridge". It is believed that the Bristol L (the tendency for the local accent to add a letter L to the end of some words) is what changed the name Brycg stowe to the current name Bristol. It appears that St Peter's church, the remains of which stand in modern Castle Park, may have been another minster, possibly with 8th-century origins. By the time of Domesday the church held three hides of land, which was a sizeable holding for a mere parish church. The Anglo-Saxon Chronicle records that in 1052 Harold Godwinson took ship to Brycgstow and later in 1062 he took ships from the town to subdue the forces of Gruffydd ap Llywelyn of Wales, indicating the status of the town as a port. Brycg stowe was a major centre for the Anglo-Saxon slave trade. Men, women and children captured in Wales or northern England were traded through Bristol to Dublin as slaves. From there the Viking rulers of Dublin would sell them on throughout the known world.
The device does not directly measure the blood sugar but rather tracks the interstitial glucose levels which are similar to blood glucose levels. The other part of the CGM, known as the transmitter, then sends the information to a receiver, an insulin pump, or a compatible smart device. Unlike the traditional glucose meter, CGMs will report the glucose level continuously and has an alarm that will alert the person if the glucose level is too high or low, helping to prevent emergencies. The device is able to graph the glucose readings over the time the sensor was in use and track trends. This allows for timely adjustment of diet, activity levels, medications, and/or illness. In addition, the information from the CGM can be downloaded and sent to a second person (such as a parent, caregiver, or partner) or physician for their review. CGMs have also been shown to improve glycemic control, reduce Hb A1c levels, and/or reduce the risk of hypoglycemic events. They also can reduce the need for multiple fingersticks throughout the day, which may be preferred by some individuals. Popular CGM devices include Dexcom, Freestyle Libre, and Medtronic. In addition to the above tests, glucose can be measured on routine labs. One common test ordered by healthcare providers is a Basic Metabolic Panel which is a blood test that looks at several different substances in the body, including blood glucose. Usually, individuals are told to fast for 8 hours before drawing the labs so that the provider can see the fasting glucose level.
Zinc is a bluish-white, lustrous, diamagnetic metal, though most common commercial grades of the metal have a dull finish. It is somewhat less dense than iron and has a hexagonal crystal structure, with a distorted form of hexagonal close packing, in which each atom has six nearest neighbors (at 265.9 pm) in its own plane and six others at a greater distance of 290.6 pm. The metal is hard and brittle at most temperatures but becomes malleable between 100 and 150 °C. Above 210 °C, the metal becomes brittle again and can be pulverized by beating. Zinc is a fair conductor of electricity. For a metal, zinc has relatively low melting (419.53 °C) and boiling point (907 °C). This melting point is the lowest of all the d-block metals aside from mercury and cadmium. For this reason among others, zinc, cadmium, and mercury are often not considered to be transition metals like the rest of the d-block metals. Many alloys contain zinc, the most famous example being brass. Other metals long known to form binary alloys with zinc are aluminium, antimony, bismuth, gold, iron, lead, mercury, silver, tin, magnesium, cobalt, nickel, tellurium, and sodium. Although neither zinc nor zirconium is ferromagnetic, their alloy, ZrZn2, exhibits ferromagnetism below 35 K.
Sources: en.wikipedia.org
The expanding liver bud is colonized by hematopoietic cells. The bipotential hepatoblasts begin differentiating into biliary epithelial cells and hepatocytes. The biliary epithelial cells differentiate from hepatoblasts around portal veins, first producing a monolayer, and then a bilayer of cuboidal cells. In ductal plate, focal dilations emerge at points in the bilayer, become surrounded by portal mesenchyme, and undergo tubulogenesis into intrahepatic bile ducts. Hepatoblasts not adjacent to portal veins instead differentiate into hepatocytes and arrange into cords lined by sinusoidal epithelial cells and bile canaliculi. Once hepatoblasts are specified into hepatocytes and undergo further expansion, they begin acquiring the functions of a mature hepatocyte, and eventually mature hepatocytes appear as highly polarized epithelial cells with abundant glycogen accumulation. In the adult liver, hepatocytes are not equivalent, with position along the portocentrovenular axis within a liver lobule dictating expression of metabolic genes involved in drug metabolism, carbohydrate metabolism, ammonia detoxification, and bile production and secretion. WNT/β-catenin has been identified as playing a key role in this phenomenon.
In the balanced budget for the 2019–20 fiscal year, worth $40 billion, the State of Illinois authorized more spending on education, including grade schools, community colleges, and state universities. Funding for grade schools rose by nearly $379 million, more than the $29 million required by the new state funding for education formula passed the previous year. Funding for community colleges increased by $14 million, and funding for public universities by $53 million. Grants for low-income students received a $50-million bump. The Illinois Department of Children and Family Services, facing financial pressure, received $80 million for hiring new staff and improving services. Moreover, the Rebuild Illinois capital plan spent $3.2 billion on public colleges and universities over six years. Pritzker created the College Student Credit Card Marketing and Debt Task Force (House Bill 1581), whose task it is to look for ways to help students reduce their credit card debts after graduation from an institution of higher education in the state. The task force was to report its findings to the General Assembly by December 4, 2019. Pritzker created a job training program for community colleges funded based on the percentage of low-income students attending. It launched in 2020. In July 2019, Pritzker signed House Bill 2512. Approved unanimously by both chambers of the Illinois General Assembly, it requires state universities to report what students pay in tuition fees to the Illinois Board of Higher Education. This is intended to increase transparency in the costs of higher education.
== Further reading == Price EJ, Rauz S, Tappuni AR, Sutcliffe N, Hackett KL, Barone F, Granata G, Ng WF, Fisher BA, Bombardieri M, Astorri E, Empson B, Larkin G, Crampton B, Bowman SJ, British Society for Rheumatology Standards, Guideline and Audit Working Group (1 October 2017). "The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome". Rheumatology. 56 (10): e24–e48. doi:10.1093/rheumatology/kex166. PMID 28957550.
=== Other === Other symptoms of CREST syndrome can be exhaustion, weakness, difficulties with breathing, pain in hands and feet, dizziness and badly healing wounds. Patients with lcSSc commonly develop pulmonary artery hypertension which may result in cor pulmonale (heart failure due to increased pulmonary artery pressure).
The size and location put a person at risk of abnormal heart rhythms (arrhythmias) or heart block, aneurysm of the heart ventricles, inflammation of the heart wall following infarction, and rupture of the heart wall that can have catastrophic consequences. Injury to the myocardium also occurs during reperfusion. This might manifest as ventricular arrhythmia. Reperfusion injury results from influx of calcium and sodium into cardiac cells and the release of oxygen free radicals. The no-reflow phenomenon (when blood remains unable to perfuse the affected myocardium despite clearing the occlusion) also contributes to myocardial injury. Local endothelial swelling is one of many factors contributing to this phenomenon.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.